tiggerpooh的个人主页 - 老虎社区

tiggerpooh

tiggerpooh

暂无个人介绍

IP属地：未知

3关注

5粉丝

0主题

0勋章

2021-06-12

Oh wow... Anyway clinical studies gotta be for years before establishment

COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart

2021-07-20

@Paperpymi[思考]

Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?

2021-11-16

Hmm

Rivian Leaps Past Volkswagen’s Valuation as EV Mania Rages

2021-11-04

Hmm good read

3 Unstoppable Stocks to Buy in a Bear Market

2021-10-18

$ContextLogic Inc.(WISH)$nothing but a wishful dream [捂脸] [流泪]

2021-12-29

Nooo

Some Vaccine Stocks Slid in Premarket Trading

2021-07-01

Apple: Act Quickly Before The Run To $172

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582024244105859","uuid":"3582024244105859","gmtCreate":1618930221300,"gmtModify":1622772965232,"name":"tiggerpooh","pinyin":"tiggerpooh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":3,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.25","exceedPercentage":"60.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":696758508,"gmtCreate":1640778352072,"gmtModify":1640778352212,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Nooo","listText":"Nooo","text":"Nooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696758508","repostId":"1120534550","repostType":2,"repost":{"id":"1120534550","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640775023,"share":"https://www.laohu8.com/m/news/1120534550?lang=&edition=full","pubTime":"2021-12-29 18:50","market":"us","language":"en","title":"Some Vaccine Stocks Slid in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1120534550","media":"Tiger Newspress","summary":"Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between ","content":"<html><head></head><body><p>Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/82a5f0fd086a4c80788994b91134d0a3\" tg-width=\"415\" tg-height=\"245\" referrerpolicy=\"no-referrer\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Vaccine Stocks Slid in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Vaccine Stocks Slid in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-29 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/82a5f0fd086a4c80788994b91134d0a3\" tg-width=\"415\" tg-height=\"245\" referrerpolicy=\"no-referrer\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120534550","content_text":"Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871249646,"gmtCreate":1637076113018,"gmtModify":1637076233551,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871249646","repostId":"1105128454","repostType":4,"isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848397069,"gmtCreate":1635961796158,"gmtModify":1635961796345,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Hmm good read","listText":"Hmm good read","text":"Hmm good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848397069","repostId":"2180378727","repostType":4,"repost":{"id":"2180378727","pubTimestamp":1635867872,"share":"https://www.laohu8.com/m/news/2180378727?lang=&edition=full","pubTime":"2021-11-02 23:44","market":"us","language":"en","title":"3 Unstoppable Stocks to Buy in a Bear Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2180378727","media":"Motley Fool","summary":"A down market is the perfect time to boost future income and juice long-term returns.","content":"<p>When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-term investors to juice their portfolios.</p>\n<p>With the market continuing to make new highs, and the only bear market in a decade coming briefly due to the pandemic, now is a good time to get a plan ready for the next one. Consider having a shopping list that has different types of stocks to take advantage of the diversity offered by both growth and income investments.</p>\n<p>The three stocks below make a good mix for the next bear market shopping list.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F645138%2Fstockinvestorthinking.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"449\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Nio: A spec for growth</h2>\n<p>Chinese electric vehicle maker <b>Nio</b> (NYSE:NIO) already has a market cap of about $65 billion, and it has yet to make a profit. That makes it speculative, and by traditional metrics, expensive. But successful growth stocks can earn their valuations quickly, and Nio is at a stage where it is starting to realize its potential.</p>\n<p>The 66,395 vehicle deliveries in the first nine months of 2021 represent growth of over 150% compared to the same period last year. Along with its manufacturing partner, it is expanding production with a new facility in Hefei, China, that will double its production capacity to at least 240,000 vehicles annually. The company has also set up a division in Norway, including its Nio House social centers, and soon will have a series of the unique battery swap stations it offers customers in China. A move into Germany is next, at the same time Nio begins selling its first sedan, the luxury ET7. The company also has two other new products planned for 2022.</p>\n<p>In its second-quarter earnings report, Nio showed it more than doubled gross margin year over year, with an adjusted loss from operations compressed by more than half versus the year-ago quarter. If the company continues to progress toward profitability in the third quarter report coming in several weeks, investors will likely continue to support its lofty valuation. As long as the bigger-picture growth story of EV adoption continues to materialize, Nio should be able to take advantage of it. Having it on the list to buy in a market decline makes sense for those who want a better price to add to existing holdings, or who feel uncomfortable investing at the current valuation.</p>\n<h2>2. Costco: Stability when needed</h2>\n<p>Warehouse retailer <b>Costco Wholesale</b> (NASDAQ:COST) is a good stock to add during a downturn both because of its long-term success and its position in the consumer staples sector. Its fortunes have led the stock to far outpace total returns of the <b>S&amp;P 500 index</b> as this 10-year chart shows.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ecc163fa7c8312600128b1cea5c3a8d\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>COST Total Return Level data by YCharts</span></p>\n<p>But maybe, more importantly, it can give investors above-average stability during an economic downturn as its customers continue to shop for necessities there. Its bulk price offerings become even more desirable for consumers when times are tight. And the annual fee isn't typically something customers look to trim during tough times. As of the end of the company's fiscal fourth quarter, membership renewal rates were over 91% in the U.S. and Canada and almost 89% globally.</p>\n<p>And Costco continues to grow its member base. It told shareholders in its recent fiscal fourth-quarter investor call that it added 1.8 million cardholders in the three-month period ended June 30, for a total membership of 111.6 million. That customer base will provide stability for both Costco and its investors during the next economic down cycle.</p>\n<h2>3. NextEra Energy: A combination of income and growth</h2>\n<p><b>NextEra Energy</b> (NYSE:NEE) is in a unique position to provide investors with income from its electric utility subsidiary while still providing exposure to the renewable energy sector with its NextEra Energy Resources clean energy business.</p>\n<p>The utility business consists of Florida Power &amp; Light and Gulf Power and gives investors stable income from a region that also is experiencing population growth. Through the recently reported 2021 third quarter, both utilities showed growth based on the average number of customer accounts versus the prior-year period for at least the eighth consecutive quarter.</p>\n<p>Besides the comfort of income coming from regulated utility businesses, investors can look to get a cheaper stake in the secular growth of renewable energy by buying NextEra during a downturn. According to NextEra, its Energy Resources subsidiary is the world's largest generator of wind and solar energy, and it also owns growing battery storage assets. Utilizing a market drop to grow a position in NextEra Energy could complement other portions of a portfolio well, and makes a good addition to the diverse group of three stocks discussed above.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks to Buy in a Bear Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks to Buy in a Bear Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 23:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NEE":"新纪元能源","COST":"好市多","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180378727","content_text":"When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-term investors to juice their portfolios.\nWith the market continuing to make new highs, and the only bear market in a decade coming briefly due to the pandemic, now is a good time to get a plan ready for the next one. Consider having a shopping list that has different types of stocks to take advantage of the diversity offered by both growth and income investments.\nThe three stocks below make a good mix for the next bear market shopping list.\nImage source: Getty Images.\n1. Nio: A spec for growth\nChinese electric vehicle maker Nio (NYSE:NIO) already has a market cap of about $65 billion, and it has yet to make a profit. That makes it speculative, and by traditional metrics, expensive. But successful growth stocks can earn their valuations quickly, and Nio is at a stage where it is starting to realize its potential.\nThe 66,395 vehicle deliveries in the first nine months of 2021 represent growth of over 150% compared to the same period last year. Along with its manufacturing partner, it is expanding production with a new facility in Hefei, China, that will double its production capacity to at least 240,000 vehicles annually. The company has also set up a division in Norway, including its Nio House social centers, and soon will have a series of the unique battery swap stations it offers customers in China. A move into Germany is next, at the same time Nio begins selling its first sedan, the luxury ET7. The company also has two other new products planned for 2022.\nIn its second-quarter earnings report, Nio showed it more than doubled gross margin year over year, with an adjusted loss from operations compressed by more than half versus the year-ago quarter. If the company continues to progress toward profitability in the third quarter report coming in several weeks, investors will likely continue to support its lofty valuation. As long as the bigger-picture growth story of EV adoption continues to materialize, Nio should be able to take advantage of it. Having it on the list to buy in a market decline makes sense for those who want a better price to add to existing holdings, or who feel uncomfortable investing at the current valuation.\n2. Costco: Stability when needed\nWarehouse retailer Costco Wholesale (NASDAQ:COST) is a good stock to add during a downturn both because of its long-term success and its position in the consumer staples sector. Its fortunes have led the stock to far outpace total returns of the S&P 500 index as this 10-year chart shows.\nCOST Total Return Level data by YCharts\nBut maybe, more importantly, it can give investors above-average stability during an economic downturn as its customers continue to shop for necessities there. Its bulk price offerings become even more desirable for consumers when times are tight. And the annual fee isn't typically something customers look to trim during tough times. As of the end of the company's fiscal fourth quarter, membership renewal rates were over 91% in the U.S. and Canada and almost 89% globally.\nAnd Costco continues to grow its member base. It told shareholders in its recent fiscal fourth-quarter investor call that it added 1.8 million cardholders in the three-month period ended June 30, for a total membership of 111.6 million. That customer base will provide stability for both Costco and its investors during the next economic down cycle.\n3. NextEra Energy: A combination of income and growth\nNextEra Energy (NYSE:NEE) is in a unique position to provide investors with income from its electric utility subsidiary while still providing exposure to the renewable energy sector with its NextEra Energy Resources clean energy business.\nThe utility business consists of Florida Power & Light and Gulf Power and gives investors stable income from a region that also is experiencing population growth. Through the recently reported 2021 third quarter, both utilities showed growth based on the average number of customer accounts versus the prior-year period for at least the eighth consecutive quarter.\nBesides the comfort of income coming from regulated utility businesses, investors can look to get a cheaper stake in the secular growth of renewable energy by buying NextEra during a downturn. According to NextEra, its Energy Resources subsidiary is the world's largest generator of wind and solar energy, and it also owns growing battery storage assets. Utilizing a market drop to grow a position in NextEra Energy could complement other portions of a portfolio well, and makes a good addition to the diverse group of three stocks discussed above.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850811771,"gmtCreate":1634570305353,"gmtModify":1634570305535,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>nothing but a wishful dream&nbsp;[捂脸]&nbsp;[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>nothing but a wishful dream&nbsp;[捂脸]&nbsp;[流泪]&nbsp;","text":"$ContextLogic Inc.(WISH)$nothing but a wishful dream [捂脸] [流泪]","images":[{"img":"https://static.tigerbbs.com/d4d9c51694a0bf2311ded49eed042f1c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850811771","isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":171128141,"gmtCreate":1626718767783,"gmtModify":1633924677228,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>[思考]&nbsp;","listText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>[思考]&nbsp;","text":"@Paperpymi[思考]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171128141","repostId":"2152363743","repostType":4,"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":151848259,"gmtCreate":1625074108871,"gmtModify":1633945092846,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>hmm","listText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>hmm","text":"@Paperpymihmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151848259","repostId":"1110936297","repostType":2,"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188621763,"gmtCreate":1623433974052,"gmtModify":1634033200461,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Oh wow... Anyway clinical studies gotta be for years before establishment&nbsp;","listText":"Oh wow... Anyway clinical studies gotta be for years before establishment&nbsp;","text":"Oh wow... Anyway clinical studies gotta be for years before establishment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188621763","repostId":"2142206311","repostType":4,"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":188621763,"gmtCreate":1623433974052,"gmtModify":1634033200461,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Oh wow... Anyway clinical studies gotta be for years before establishment&nbsp;","listText":"Oh wow... Anyway clinical studies gotta be for years before establishment&nbsp;","text":"Oh wow... Anyway clinical studies gotta be for years before establishment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188621763","repostId":"2142206311","repostType":4,"repost":{"id":"2142206311","pubTimestamp":1623426552,"share":"https://www.laohu8.com/m/news/2142206311?lang=&edition=full","pubTime":"2021-06-11 23:49","market":"us","language":"en","title":"COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart","url":"https://stock-news.laohu8.com/highlight/detail?id=2142206311","media":"Zacks","summary":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention  stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS  following dose 1 of any mR","content":"<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from <b>Moderna</b> MRNA, and <b>Pfizer</b> PFE/<b>BioNTech</b> BNTX.</p><p>Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with <b>J&amp;J</b>’s JNJ adenovirus-based COVID-19 vaccine.</p><h3>Israeli Alarm</h3><p>Per a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.</p><p>Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.</p><h3>CDC Meeting</h3><p>We note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.</p><p>However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.</p><h3>mRNA Vaccine Updates</h3><p>We remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.</p><p>Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.</p><p>While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). </p><p>Pfizer,&nbsp;Moderna&nbsp;fell&nbsp;over&nbsp;1%&nbsp;in&nbsp;morning&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/4abafe1ebf6b0259e6f305a5483d4a2a\" tg-width=\"700\" tg-height=\"584\"><img src=\"https://static.tigerbbs.com/16bd6a310a9f80f7ecaf40c96b582198\" tg-width=\"700\" tg-height=\"584\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/i.kaShYr9WLQwJ3VXlE4CA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/aNEP4MqN0KfFI8mDHT.6JQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0bba00e006cf8b1987f4ca39d28c5938","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/covid-19-jabs-pfizer-moderna-124412703.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142206311","content_text":"The COVID-19 vaccine task force of the U.S. Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of heart inflammation in adolescents and younger adults, especially aged 12 to 24, following inoculation with authorized mRNA-based COVID-19 vaccines from Moderna MRNA, and Pfizer PFE/BioNTech BNTX.Several hundreds of cases of myocarditis and pericarditis, both conditions of heart inflammation, were reported to the U.S. government’s VAERS (Vaccine Adverse Event Reporting System) following dose 1 of any mRNA-based vaccine in the last two months. Please note that VAERS is a national early warning system to detect possible safety problems in U.S. licensed vaccines. The number of cases increased further after the second dose of these vaccines. Moreover, the cases occurred in higher number of younger patients following dose 2 compared to dose 1. The CDC stated that similar inflammation cases were not reported following vaccination with J&J’s JNJ adenovirus-based COVID-19 vaccine.Israeli AlarmPer a Reuters report, the Israel’s Health Ministry raised the alarm when it reported a likely link of heart inflammation in young men vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries started investigating such cases.Although the number of reported cases is small compared to total inoculations with mRNA vaccines, they were higher than expected in the younger age groups.CDC MeetingWe note that the CDC is yet to link these adverse events to mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practices (ACIP) on Jun 18 to discuss and assess the heart inflammation reports. Moreover, the government authority has recommended continuation of vaccination for everyone of age 12 or older given the risk of COVID-19 illness and related complications.However, we note that the CDC report also stated that more than 50% of heart inflammation cases were reported in the age group of 12-24 that has received only 8.8% of vaccine doses. This suggests that any adverse outcome from the ACIP meeting scheduled next week can hamper vaccination with mRNA vaccines in the adolescent patient group, and hurt prospects of these vaccine developers. However, the percentage of inflammation cases suggests that the risk from these vaccines is significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. Moreover, most patients facing inflammation issues quickly felt better following medication and rest.mRNA Vaccine UpdatesWe remind investors that Pfizer/BioNTech’s COVID-19 vaccine received authorization for emergency use in adolescents last month from the FDA. Moderna filed for a similar authorization in the United States, Europe and Canada earlier this month.Meanwhile, Pfizer and BioNTech have pledged two billion doses of their COVID-19 vaccines to ensure equitable access to their vaccines globally. As part of the pledge, the company plans to supply 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at not-for-profit price. The government will donate these doses to low- and lower middle-income countries and organizations that support them.While Moderna and Pfizer carry a Zacks Rank #3 (Hold), BioNTech sports a Zacks Rank of 1 (Strong Buy). Pfizer, Moderna fell over 1% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171128141,"gmtCreate":1626718767783,"gmtModify":1633924677228,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>[思考]&nbsp;","listText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>[思考]&nbsp;","text":"@Paperpymi[思考]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171128141","repostId":"2152363743","repostType":4,"repost":{"id":"2152363743","pubTimestamp":1626703200,"share":"https://www.laohu8.com/m/news/2152363743?lang=&edition=full","pubTime":"2021-07-19 22:00","market":"us","language":"en","title":"Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2152363743","media":"Motley Fool","summary":"There's no guarantee that the biotech's share price will continue climbing.","content":"<p>(July&nbsp;19)&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> &nbsp;rose&nbsp;more&nbsp;than&nbsp;5%&nbsp;in&nbsp;morning&nbsp;tarding,&nbsp;reached&nbsp;record&nbsp;high.</p>\n<p><img src=\"https://static.tigerbbs.com/1feabb7b1efe112684a8cca75133e6a3\" tg-width=\"642\" tg-height=\"460\" referrerpolicy=\"no-referrer\"></p>\n<p>You never hear anyone refer to the \"S&amp;P 501 index\" or the \"S&amp;P 499 index.\" No, it's the <b>S&amp;P 500 index</b>, for a good reason: The index always includes the 500 largest companies that trade on U.S. stock exchanges. When <a href=\"https://laohu8.com/S/AONE.U\">one</a> company is removed from the list, another <a href=\"https://laohu8.com/S/AONE.U\">one</a> is added. Always.</p>\n<p>That's what is about to happen. <b><a href=\"https://laohu8.com/S/ALXN\">Alexion Pharmaceuticals</a></b> currently ranks as one of only six biotech stocks on the S&amp;P 500. However, <b>AstraZeneca</b> will soon acquire the company, meaning <b>S&amp;P Global</b> (NYSE:SPGI) will have to replace Alexion on its heavily followed index.</p>\n<p>As it turns out, another biotech stock is set to take Alexion's spot: <b>Moderna</b> (NASDAQ:MRNA). S&amp;P Global announced last Thursday evening that Moderna would be added to the S&amp;P 500, effective prior to the market open on July 21. Shares of Moderna jumped over 10% on Friday, after soaring nearly 150% year to date already. What's next for this hot vaccine stock?</p>\n<p><img src=\"https://static.tigerbbs.com/182332242f3e0118e76d38617bff229c\" tg-width=\"700\" tg-height=\"408\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Using the past as a guide</h3>\n<p>There's an old saying that \"history doesn't repeat itself, but it often rhymes.\" Assuming the adage has some truth to it, we could potentially learn how Moderna's share price might fare by looking at what happened with other stocks that were added to the S&amp;P 500.</p>\n<p>So far in 2021, 10 stocks have been added to the index as a result of acquisitions, spinoffs, and market-cap changes.</p>\n<p>The most recent of these was <b>Organon</b> (NYSE:OGN). S&amp;P Global announced on May 27 that the drugmaker, which was spun off from <b><a href=\"https://laohu8.com/S/MRK\">Merck</a></b>, would be added to the S&amp;P 500 index, effective June 4. Organon's shares climbed only around 4% between the date of the announcement and its addition to the index. But afterward, the pharma stock fell close to 15%.</p>\n<p>S&amp;P Global announced on May 10 that <b><a href=\"https://laohu8.com/S/CRL\">Charles River Laboratories</a></b> (NYSE:CRL) would join the S&amp;P 500 index effective May 14. The diagnostics stock fell a little in the days leading up to its addition to the index. However, after its inclusion on the S&amp;P 500, Charles River Labs stock went on a roll, rising nearly 17%.</p>\n<p>There is one stock that might offer a closer parallel to Moderna. <b>NXP Semiconductors</b> (NASDAQ:NXPI) stock jumped around 10% between the announcement of its addition to the S&amp;P 500 on March 12, and when it joined the index on March 22. That's nearly exactly the same level as Moderna's shares leaped on Friday. So what happened next with NXP? The stock moved up and down like a yo-yo, and is now 5% lower.</p>\n<h3>Different dynamics</h3>\n<p>You've probably decided that history is a poor rhymer -- at least when it comes to how stocks perform when they're added to the S&amp;P 500 index. There's a good reason why it's hard to discern a clear pattern: Each stock has different dynamics at work.</p>\n<p>Sure, mutual funds and exchange-traded funds (ETFs) that track the S&amp;P 500 index must now add shares of Moderna to their holdings. However, they were likely already doing so to some extent, even before the announcement about Moderna's addition to the index.</p>\n<p>What matters most for Moderna stock now is exactly the same thing that mattered most before last Thursday. And that critical factor is how demand for the company's COVID-19 vaccine will hold up.</p>\n<p>Based on the stock's trajectory in the weeks and months leading up to S&amp;P Global's announcement that Moderna was replacing Alexion in the S&amp;P 500, investors are expecting that demand for Moderna's vaccine will remain quite strong. They could very well be right.</p>\n<h3>The variant variable</h3>\n<p>However, whether or not investors' optimism is warranted depends on one variable that is most likely to impact Moderna's fortunes over the coming months and years: the emergence of coronavirus variants of concern. Right now, the most important to watch is the Delta variant.</p>\n<p>So far, Moderna's COVID-19 vaccine appears to be holding up relatively well against the Delta variant, as well as against other variants of concern. However, there's a real possibility that booster doses could be needed for at least some individuals in the not-too-distant future. Also, other variants could arise for which current vaccines are significantly less effective.</p>\n<p>For Moderna to remain a member of the S&amp;P 500, its market cap must remain large enough to be among the top 500 stocks. Whether that will happen depends on recurring demand for its COVID-19 vaccine. And that demand depends largely how coronavirus variants affect the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-19 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/19/modernas-joining-the-sp-500-whats-next-for-the-hot/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(July 19) Moderna, Inc.  rose more than 5% in morning tarding, reached record high.\n\nYou never hear anyone refer to the \"S&P 501 index\" or the \"S&P 499 index.\" No, it's the S&P 500 index, for a good ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/19/modernas-joining-the-sp-500-whats-next-for-the-hot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/182332242f3e0118e76d38617bff229c","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","IVV":"标普500指数ETF",".SPX":"S&P 500 Index","SSO":"两倍做多标普500ETF","OEX":"标普100","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF"},"source_url":"https://www.fool.com/investing/2021/07/19/modernas-joining-the-sp-500-whats-next-for-the-hot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152363743","content_text":"(July 19) Moderna, Inc.  rose more than 5% in morning tarding, reached record high.\n\nYou never hear anyone refer to the \"S&P 501 index\" or the \"S&P 499 index.\" No, it's the S&P 500 index, for a good reason: The index always includes the 500 largest companies that trade on U.S. stock exchanges. When one company is removed from the list, another one is added. Always.\nThat's what is about to happen. Alexion Pharmaceuticals currently ranks as one of only six biotech stocks on the S&P 500. However, AstraZeneca will soon acquire the company, meaning S&P Global (NYSE:SPGI) will have to replace Alexion on its heavily followed index.\nAs it turns out, another biotech stock is set to take Alexion's spot: Moderna (NASDAQ:MRNA). S&P Global announced last Thursday evening that Moderna would be added to the S&P 500, effective prior to the market open on July 21. Shares of Moderna jumped over 10% on Friday, after soaring nearly 150% year to date already. What's next for this hot vaccine stock?\n\nImage source: Getty Images.\nUsing the past as a guide\nThere's an old saying that \"history doesn't repeat itself, but it often rhymes.\" Assuming the adage has some truth to it, we could potentially learn how Moderna's share price might fare by looking at what happened with other stocks that were added to the S&P 500.\nSo far in 2021, 10 stocks have been added to the index as a result of acquisitions, spinoffs, and market-cap changes.\nThe most recent of these was Organon (NYSE:OGN). S&P Global announced on May 27 that the drugmaker, which was spun off from Merck, would be added to the S&P 500 index, effective June 4. Organon's shares climbed only around 4% between the date of the announcement and its addition to the index. But afterward, the pharma stock fell close to 15%.\nS&P Global announced on May 10 that Charles River Laboratories (NYSE:CRL) would join the S&P 500 index effective May 14. The diagnostics stock fell a little in the days leading up to its addition to the index. However, after its inclusion on the S&P 500, Charles River Labs stock went on a roll, rising nearly 17%.\nThere is one stock that might offer a closer parallel to Moderna. NXP Semiconductors (NASDAQ:NXPI) stock jumped around 10% between the announcement of its addition to the S&P 500 on March 12, and when it joined the index on March 22. That's nearly exactly the same level as Moderna's shares leaped on Friday. So what happened next with NXP? The stock moved up and down like a yo-yo, and is now 5% lower.\nDifferent dynamics\nYou've probably decided that history is a poor rhymer -- at least when it comes to how stocks perform when they're added to the S&P 500 index. There's a good reason why it's hard to discern a clear pattern: Each stock has different dynamics at work.\nSure, mutual funds and exchange-traded funds (ETFs) that track the S&P 500 index must now add shares of Moderna to their holdings. However, they were likely already doing so to some extent, even before the announcement about Moderna's addition to the index.\nWhat matters most for Moderna stock now is exactly the same thing that mattered most before last Thursday. And that critical factor is how demand for the company's COVID-19 vaccine will hold up.\nBased on the stock's trajectory in the weeks and months leading up to S&P Global's announcement that Moderna was replacing Alexion in the S&P 500, investors are expecting that demand for Moderna's vaccine will remain quite strong. They could very well be right.\nThe variant variable\nHowever, whether or not investors' optimism is warranted depends on one variable that is most likely to impact Moderna's fortunes over the coming months and years: the emergence of coronavirus variants of concern. Right now, the most important to watch is the Delta variant.\nSo far, Moderna's COVID-19 vaccine appears to be holding up relatively well against the Delta variant, as well as against other variants of concern. However, there's a real possibility that booster doses could be needed for at least some individuals in the not-too-distant future. Also, other variants could arise for which current vaccines are significantly less effective.\nFor Moderna to remain a member of the S&P 500, its market cap must remain large enough to be among the top 500 stocks. Whether that will happen depends on recurring demand for its COVID-19 vaccine. And that demand depends largely how coronavirus variants affect the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871249646,"gmtCreate":1637076113018,"gmtModify":1637076233551,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871249646","repostId":"1105128454","repostType":4,"repost":{"id":"1105128454","pubTimestamp":1637075732,"share":"https://www.laohu8.com/m/news/1105128454?lang=&edition=full","pubTime":"2021-11-16 23:15","market":"us","language":"en","title":"Rivian Leaps Past Volkswagen’s Valuation as EV Mania Rages","url":"https://stock-news.laohu8.com/highlight/detail?id=1105128454","media":"Bloomberg","summary":"A searing five-day rally in the shares of Rivian Automotive Inc. has led the electric-truck startup ","content":"<p>A searing five-day rally in the shares of Rivian Automotive Inc. has led the electric-truck startup to more than double in value since last-week’s trading debut, with its market capitalization now surpassing Volkswagen AG.</p>\n<p>The stock jumped as much as 10% to $164.60 in New York on Tuesday, up 111% from the initial public offering price of $78. That brought the company’s market valuation to $143.5 billion, easily topping the list of biggest U.S. companies with no sales.</p>\n<p>Rivian, which is backed by Amazon and Ford, overtook Volkswagen’s market capitalization of $138.9 billion, as investors eager to get into the EV sector now have another stock to invest in, apart from industry trailblazer Tesla Inc.</p>\n<p>The rally since its IPO also makes Rivian’s the year’s second-best debut week, behind Affirm Holdings Inc., which gained 117% during its first five sessions. This data excludes IPOs that raised less than $1 billion.</p>\n<p>EV stocks of all stripes and colors have also seen heightened interest from retail investors in recent weeks, with Rivian, Lucid and Tesla topping Fidelity’s retail trading platform’s list of most bought assets on Tuesday.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian Leaps Past Volkswagen’s Valuation as EV Mania Rages</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian Leaps Past Volkswagen’s Valuation as EV Mania Rages\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-16 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/rivian-leaps-past-volkswagen-valuation-145011593.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A searing five-day rally in the shares of Rivian Automotive Inc. has led the electric-truck startup to more than double in value since last-week’s trading debut, with its market capitalization now ...</p>\n\n<a href=\"https://finance.yahoo.com/news/rivian-leaps-past-volkswagen-valuation-145011593.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://finance.yahoo.com/news/rivian-leaps-past-volkswagen-valuation-145011593.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105128454","content_text":"A searing five-day rally in the shares of Rivian Automotive Inc. has led the electric-truck startup to more than double in value since last-week’s trading debut, with its market capitalization now surpassing Volkswagen AG.\nThe stock jumped as much as 10% to $164.60 in New York on Tuesday, up 111% from the initial public offering price of $78. That brought the company’s market valuation to $143.5 billion, easily topping the list of biggest U.S. companies with no sales.\nRivian, which is backed by Amazon and Ford, overtook Volkswagen’s market capitalization of $138.9 billion, as investors eager to get into the EV sector now have another stock to invest in, apart from industry trailblazer Tesla Inc.\nThe rally since its IPO also makes Rivian’s the year’s second-best debut week, behind Affirm Holdings Inc., which gained 117% during its first five sessions. This data excludes IPOs that raised less than $1 billion.\nEV stocks of all stripes and colors have also seen heightened interest from retail investors in recent weeks, with Rivian, Lucid and Tesla topping Fidelity’s retail trading platform’s list of most bought assets on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848397069,"gmtCreate":1635961796158,"gmtModify":1635961796345,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Hmm good read","listText":"Hmm good read","text":"Hmm good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848397069","repostId":"2180378727","repostType":4,"repost":{"id":"2180378727","pubTimestamp":1635867872,"share":"https://www.laohu8.com/m/news/2180378727?lang=&edition=full","pubTime":"2021-11-02 23:44","market":"us","language":"en","title":"3 Unstoppable Stocks to Buy in a Bear Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2180378727","media":"Motley Fool","summary":"A down market is the perfect time to boost future income and juice long-term returns.","content":"<p>When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-term investors to juice their portfolios.</p>\n<p>With the market continuing to make new highs, and the only bear market in a decade coming briefly due to the pandemic, now is a good time to get a plan ready for the next one. Consider having a shopping list that has different types of stocks to take advantage of the diversity offered by both growth and income investments.</p>\n<p>The three stocks below make a good mix for the next bear market shopping list.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F645138%2Fstockinvestorthinking.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"449\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Nio: A spec for growth</h2>\n<p>Chinese electric vehicle maker <b>Nio</b> (NYSE:NIO) already has a market cap of about $65 billion, and it has yet to make a profit. That makes it speculative, and by traditional metrics, expensive. But successful growth stocks can earn their valuations quickly, and Nio is at a stage where it is starting to realize its potential.</p>\n<p>The 66,395 vehicle deliveries in the first nine months of 2021 represent growth of over 150% compared to the same period last year. Along with its manufacturing partner, it is expanding production with a new facility in Hefei, China, that will double its production capacity to at least 240,000 vehicles annually. The company has also set up a division in Norway, including its Nio House social centers, and soon will have a series of the unique battery swap stations it offers customers in China. A move into Germany is next, at the same time Nio begins selling its first sedan, the luxury ET7. The company also has two other new products planned for 2022.</p>\n<p>In its second-quarter earnings report, Nio showed it more than doubled gross margin year over year, with an adjusted loss from operations compressed by more than half versus the year-ago quarter. If the company continues to progress toward profitability in the third quarter report coming in several weeks, investors will likely continue to support its lofty valuation. As long as the bigger-picture growth story of EV adoption continues to materialize, Nio should be able to take advantage of it. Having it on the list to buy in a market decline makes sense for those who want a better price to add to existing holdings, or who feel uncomfortable investing at the current valuation.</p>\n<h2>2. Costco: Stability when needed</h2>\n<p>Warehouse retailer <b>Costco Wholesale</b> (NASDAQ:COST) is a good stock to add during a downturn both because of its long-term success and its position in the consumer staples sector. Its fortunes have led the stock to far outpace total returns of the <b>S&amp;P 500 index</b> as this 10-year chart shows.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ecc163fa7c8312600128b1cea5c3a8d\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>COST Total Return Level data by YCharts</span></p>\n<p>But maybe, more importantly, it can give investors above-average stability during an economic downturn as its customers continue to shop for necessities there. Its bulk price offerings become even more desirable for consumers when times are tight. And the annual fee isn't typically something customers look to trim during tough times. As of the end of the company's fiscal fourth quarter, membership renewal rates were over 91% in the U.S. and Canada and almost 89% globally.</p>\n<p>And Costco continues to grow its member base. It told shareholders in its recent fiscal fourth-quarter investor call that it added 1.8 million cardholders in the three-month period ended June 30, for a total membership of 111.6 million. That customer base will provide stability for both Costco and its investors during the next economic down cycle.</p>\n<h2>3. NextEra Energy: A combination of income and growth</h2>\n<p><b>NextEra Energy</b> (NYSE:NEE) is in a unique position to provide investors with income from its electric utility subsidiary while still providing exposure to the renewable energy sector with its NextEra Energy Resources clean energy business.</p>\n<p>The utility business consists of Florida Power &amp; Light and Gulf Power and gives investors stable income from a region that also is experiencing population growth. Through the recently reported 2021 third quarter, both utilities showed growth based on the average number of customer accounts versus the prior-year period for at least the eighth consecutive quarter.</p>\n<p>Besides the comfort of income coming from regulated utility businesses, investors can look to get a cheaper stake in the secular growth of renewable energy by buying NextEra during a downturn. According to NextEra, its Energy Resources subsidiary is the world's largest generator of wind and solar energy, and it also owns growing battery storage assets. Utilizing a market drop to grow a position in NextEra Energy could complement other portions of a portfolio well, and makes a good addition to the diverse group of three stocks discussed above.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks to Buy in a Bear Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks to Buy in a Bear Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 23:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NEE":"新纪元能源","COST":"好市多","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/11/02/3-unstoppable-stocks-to-buy-in-a-bear-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180378727","content_text":"When the market is tumbling, many investors find themselves either frozen by fear or having too many choices to make a decision. But corrections and bear markets are the best opportunities for long-term investors to juice their portfolios.\nWith the market continuing to make new highs, and the only bear market in a decade coming briefly due to the pandemic, now is a good time to get a plan ready for the next one. Consider having a shopping list that has different types of stocks to take advantage of the diversity offered by both growth and income investments.\nThe three stocks below make a good mix for the next bear market shopping list.\nImage source: Getty Images.\n1. Nio: A spec for growth\nChinese electric vehicle maker Nio (NYSE:NIO) already has a market cap of about $65 billion, and it has yet to make a profit. That makes it speculative, and by traditional metrics, expensive. But successful growth stocks can earn their valuations quickly, and Nio is at a stage where it is starting to realize its potential.\nThe 66,395 vehicle deliveries in the first nine months of 2021 represent growth of over 150% compared to the same period last year. Along with its manufacturing partner, it is expanding production with a new facility in Hefei, China, that will double its production capacity to at least 240,000 vehicles annually. The company has also set up a division in Norway, including its Nio House social centers, and soon will have a series of the unique battery swap stations it offers customers in China. A move into Germany is next, at the same time Nio begins selling its first sedan, the luxury ET7. The company also has two other new products planned for 2022.\nIn its second-quarter earnings report, Nio showed it more than doubled gross margin year over year, with an adjusted loss from operations compressed by more than half versus the year-ago quarter. If the company continues to progress toward profitability in the third quarter report coming in several weeks, investors will likely continue to support its lofty valuation. As long as the bigger-picture growth story of EV adoption continues to materialize, Nio should be able to take advantage of it. Having it on the list to buy in a market decline makes sense for those who want a better price to add to existing holdings, or who feel uncomfortable investing at the current valuation.\n2. Costco: Stability when needed\nWarehouse retailer Costco Wholesale (NASDAQ:COST) is a good stock to add during a downturn both because of its long-term success and its position in the consumer staples sector. Its fortunes have led the stock to far outpace total returns of the S&P 500 index as this 10-year chart shows.\nCOST Total Return Level data by YCharts\nBut maybe, more importantly, it can give investors above-average stability during an economic downturn as its customers continue to shop for necessities there. Its bulk price offerings become even more desirable for consumers when times are tight. And the annual fee isn't typically something customers look to trim during tough times. As of the end of the company's fiscal fourth quarter, membership renewal rates were over 91% in the U.S. and Canada and almost 89% globally.\nAnd Costco continues to grow its member base. It told shareholders in its recent fiscal fourth-quarter investor call that it added 1.8 million cardholders in the three-month period ended June 30, for a total membership of 111.6 million. That customer base will provide stability for both Costco and its investors during the next economic down cycle.\n3. NextEra Energy: A combination of income and growth\nNextEra Energy (NYSE:NEE) is in a unique position to provide investors with income from its electric utility subsidiary while still providing exposure to the renewable energy sector with its NextEra Energy Resources clean energy business.\nThe utility business consists of Florida Power & Light and Gulf Power and gives investors stable income from a region that also is experiencing population growth. Through the recently reported 2021 third quarter, both utilities showed growth based on the average number of customer accounts versus the prior-year period for at least the eighth consecutive quarter.\nBesides the comfort of income coming from regulated utility businesses, investors can look to get a cheaper stake in the secular growth of renewable energy by buying NextEra during a downturn. According to NextEra, its Energy Resources subsidiary is the world's largest generator of wind and solar energy, and it also owns growing battery storage assets. Utilizing a market drop to grow a position in NextEra Energy could complement other portions of a portfolio well, and makes a good addition to the diverse group of three stocks discussed above.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850811771,"gmtCreate":1634570305353,"gmtModify":1634570305535,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>nothing but a wishful dream&nbsp;[捂脸]&nbsp;[流泪]&nbsp;","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>nothing but a wishful dream&nbsp;[捂脸]&nbsp;[流泪]&nbsp;","text":"$ContextLogic Inc.(WISH)$nothing but a wishful dream [捂脸] [流泪]","images":[{"img":"https://static.tigerbbs.com/d4d9c51694a0bf2311ded49eed042f1c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850811771","isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":696758508,"gmtCreate":1640778352072,"gmtModify":1640778352212,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"Nooo","listText":"Nooo","text":"Nooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696758508","repostId":"1120534550","repostType":2,"repost":{"id":"1120534550","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640775023,"share":"https://www.laohu8.com/m/news/1120534550?lang=&edition=full","pubTime":"2021-12-29 18:50","market":"us","language":"en","title":"Some Vaccine Stocks Slid in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1120534550","media":"Tiger Newspress","summary":"Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between ","content":"<html><head></head><body><p>Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/82a5f0fd086a4c80788994b91134d0a3\" tg-width=\"415\" tg-height=\"245\" referrerpolicy=\"no-referrer\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Vaccine Stocks Slid in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Vaccine Stocks Slid in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-29 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.</p><p><img src=\"https://static.tigerbbs.com/82a5f0fd086a4c80788994b91134d0a3\" tg-width=\"415\" tg-height=\"245\" referrerpolicy=\"no-referrer\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120534550","content_text":"Some vaccine stocks slid in premarket trading.BioNTech SE, Moderna, Pfizer and Novavax fell between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":151848259,"gmtCreate":1625074108871,"gmtModify":1633945092846,"author":{"id":"3582024244105859","authorId":"3582024244105859","name":"tiggerpooh","avatar":"https://static.tigerbbs.com/24bf771f56f6ca91571107be4b6cc295","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582024244105859","authorIdStr":"3582024244105859"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>hmm","listText":"<a href=\"https://laohu8.com/U/3574827569068838\">@Paperpymi</a>hmm","text":"@Paperpymihmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151848259","repostId":"1110936297","repostType":2,"repost":{"id":"1110936297","pubTimestamp":1625036047,"share":"https://www.laohu8.com/m/news/1110936297?lang=&edition=full","pubTime":"2021-06-30 14:54","market":"us","language":"en","title":"Apple: Act Quickly Before The Run To $172","url":"https://stock-news.laohu8.com/highlight/detail?id=1110936297","media":"seekingalpha","summary":"Apple faces many external threats from regulators in the developed world.But I see these as largely priced in, although they remain a threat longer term.Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.I have made it no secret that I’m a big fan of Apple. In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Apple faces many external threats from regulators in the developed world.</li>\n <li>But I see these as largely priced in, although they remain a threat longer term.</li>\n <li>Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/219c4f41554f7e91be4c02cd87e3f8d6\" tg-width=\"1536\" tg-height=\"1024\"><span>fMing Yeung/Getty Images News</span></p>\n<p>I have made it no secret that I’m a big fan of&nbsp;<b>Apple</b>(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a&nbsp;big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/37078c4ff01404a43176bb2e2555834d\" tg-width=\"640\" tg-height=\"615\"><span>Source: StockCharts</span></p>\n<p>To start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.</p>\n<p>Ascending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.</p>\n<p>What do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.</p>\n<p>Finally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has been<i>very</i>reliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.</p>\n<p>The important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.</p>\n<p>To be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.</p>\n<p>The risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.</p>\n<p><b>Why does Apple rally pre-earnings?</b></p>\n<p>To put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6233212bc10ea38f20e75d2ed0ab603e\" tg-width=\"640\" tg-height=\"284\"><span>Source:Seeking Alpha</span></p>\n<p>This is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.</p>\n<p>Keep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.</p>\n<p>In terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ebf56ca48e2364fd7314f9140bc3ab5c\" tg-width=\"640\" tg-height=\"286\"><span>Source:Seeking Alpha</span></p>\n<p>The sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d2bd9aaadd1cc3a29d7b8e787296ab4b\" tg-width=\"454\" tg-height=\"110\"><span>Source:Seeking Alpha</span></p>\n<p>I think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and<i>100%</i>of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.</p>\n<p><b>Not all is well</b></p>\n<p>Apple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.</p>\n<p>First, the FTC made the headlines a few weeks ago by appointing&nbsp;Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.</p>\n<p>The&nbsp;White Houseis apparently on board with this line of thinking, and the&nbsp;House&nbsp;is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't a<i>positive</i>&nbsp;catalyst.</p>\n<p>Apple is facing a similar threat in&nbsp;Germany&nbsp;and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).</p>\n<p>Apple is also still very much beholden to the never-ending trade war between&nbsp;China&nbsp;and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.</p>\n<p><b>Final thoughts</b></p>\n<p>I’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.</p>\n<p>The threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.</p>\n<p>Keep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.</p>\n<p>I detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the&nbsp;prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.</p>\n<p>The important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.</p>\n<p>The bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: Act Quickly Before The Run To $172</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: Act Quickly Before The Run To $172\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should ...</p>\n\n<a href=\"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110936297","content_text":"Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.\n\nfMing Yeung/Getty Images News\nI have made it no secret that I’m a big fan of Apple(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.\nSource: StockCharts\nTo start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.\nAscending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.\nWhat do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.\nFinally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has beenveryreliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.\nThe important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.\nTo be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.\nThe risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.\nWhy does Apple rally pre-earnings?\nTo put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.\nSource:Seeking Alpha\nThis is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.\nKeep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.\nIn terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.\nSource:Seeking Alpha\nThe sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.\nSource:Seeking Alpha\nI think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and100%of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.\nNot all is well\nApple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.\nFirst, the FTC made the headlines a few weeks ago by appointing Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.\nThe White Houseis apparently on board with this line of thinking, and the House is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't apositive catalyst.\nApple is facing a similar threat in Germany and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).\nApple is also still very much beholden to the never-ending trade war between China and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.\nFinal thoughts\nI’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.\nThe threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.\nKeep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.\nI detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.\nThe important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.\nThe bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.","news_type":1},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}